M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - FRA:M12 - DE000A0STSQ8 - Common Stock
15.9 EUR
+0.3 (+1.92%)
We assign a fundamental rating of 7 out of 10 to M12. M12 was compared to 31 industry peers in the Health Care Providers & Services industry. M12 gets an excellent profitability rating and is at the same time showing great financial health properties. M12 is not valued too expensively and it also shows a decent growth rate. With these ratings, M12 could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
M12 had positive earnings in the past year.
M12 had a positive operating cash flow in the past year.
In the past 5 years M12 has always been profitable.
M12 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.73%, M12 belongs to the top of the industry, outperforming 96.77% of the companies in the same industry.
With a decent Return On Equity value of 15.03%, M12 is doing good in the industry, outperforming 77.42% of the companies in the same industry.
M12 has a better Return On Invested Capital (13.44%) than 90.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 6.75%.
The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
M12 has a Profit Margin of 5.00%. This is amongst the best in the industry. M12 outperforms 83.87% of its industry peers.
In the last couple of years the Profit Margin of M12 has declined.
M12 has a better Operating Margin (8.52%) than 74.19% of its industry peers.
In the last couple of years the Operating Margin of M12 has declined.
M12's Gross Margin of 19.29% is in line compared to the rest of the industry. M12 outperforms 41.94% of its industry peers.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so M12 is creating value.
M12 has less shares outstanding than it did 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for M12 is higher compared to a year ago.
2.2 Solvency
M12 has an Altman-Z score of 5.37. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
M12 has a better Altman-Z score (5.37) than 100.00% of its industry peers.
The Debt to FCF ratio of M12 is 0.70, which is an excellent value as it means it would take M12, only 0.70 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.70, M12 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that M12 is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, M12 belongs to the top of the industry, outperforming 96.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.37 |
ROIC/WACC1.86
WACC7.23%
2.3 Liquidity
M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
M12 has a Current ratio of 2.06. This is amongst the best in the industry. M12 outperforms 90.32% of its industry peers.
A Quick Ratio of 1.35 indicates that M12 should not have too much problems paying its short term obligations.
M12 has a better Quick ratio (1.35) than 80.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
M12 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.36%, which is quite good.
Measured over the past 5 years, M12 shows a small growth in Earnings Per Share. The EPS has been growing by 7.97% on average per year.
Looking at the last year, M12 shows a small growth in Revenue. The Revenue has grown by 6.52% in the last year.
The Revenue has been growing by 34.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
Based on estimates for the next years, M12 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.18% on average per year.
The Revenue is expected to grow by 8.24% on average over the next years. This is quite good.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
M12 is valuated correctly with a Price/Earnings ratio of 16.91.
Based on the Price/Earnings ratio, M12 is valued a bit cheaper than 61.29% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.46, M12 is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 13.70, the valuation of M12 can be described as correct.
64.52% of the companies in the same industry are more expensive than M12, based on the Price/Forward Earnings ratio.
M12's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.91 | ||
| Fwd PE | 13.7 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 74.19% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, M12 is valued a bit cheaper than the industry average as 70.97% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.7 | ||
| EV/EBITDA | 7.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of M12 may justify a higher PE ratio.
M12's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.26
PEG (5Y)2.12
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.47%.
Compared to an average industry Dividend Yield of 2.44, M12 pays a better dividend. On top of this M12 pays more dividend than 93.55% of the companies listed in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (11/19/2025, 7:00:00 PM)
15.9
+0.3 (+1.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap312.28M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (70%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.91 | ||
| Fwd PE | 13.7 | ||
| P/S | 0.88 | ||
| P/FCF | 11.7 | ||
| P/OCF | 11.55 | ||
| P/B | 2.65 | ||
| P/tB | 11.37 | ||
| EV/EBITDA | 7.53 |
EPS(TTM)0.94
EY5.91%
EPS(NY)1.16
Fwd EY7.3%
FCF(TTM)1.36
FCFY8.55%
OCF(TTM)1.38
OCFY8.66%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.26
PEG (5Y)2.12
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.37 |
F-Score9
WACC7.23%
ROIC/WACC1.86
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year31.44%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 7 / 10 to M12.DE.
Can you provide the valuation status for M1 KLINIKEN AG?
ChartMill assigns a valuation rating of 5 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of M1 KLINIKEN AG (M12.DE) stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 16.91 and the Price/Book (PB) ratio is 2.65.